Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Nutcracker Therapeutics, Inc.

Nutcracker Therapeutics Unveils NMU-Symphony™ System for On-demand, Individualized Manufacture of RNA-based Personalized Therapeutics
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics to Showcase NMU-Symphony™ Platform for Personalized Cancer Therapeutics at Leading Industry Conferences
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics CEO Dr. Igor Khandros Retires as Company Continues Evolution as an RNA Therapeutics CRDMO
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Presents Precision Biomanufacturing and CRDMO Solutions at the 2024 Personalized Cancer Vaccine Summit
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Announces Publication in ACS Nano Demonstrating the Therapeutic Viability of Nutshell® Delivery Vehicles
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Demonstrates Enhanced Activity of B Cell Lymphoma Candidate NTX-472 at the 2024 ASCO Annual Meeting
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology Innovation Forum
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics’ Research Partner, the University of California, San Francisco, Presents Foundational Prostate Cancer Data at AAI 2024
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics to Present Data for Two mRNA Drug Candidates at SITC 2023
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics appoints Cynthia Collins, biopharma veteran and former Editas Medicine CEO, to board of directors
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Presenting on Nutshell™ mRNA Delivery Technology at the 2023 Oligonucleotide and Peptide Therapeutics Conference
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Appoints Industry Veteran Angela Peters as Chief Human Resources Officer
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Adds Dr. Thomas J. Dietz to Board of Directors
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics to Present Data for Lead Candidate at 2022 SITC Annual Meeting
From Nutcracker Therapeutics, Inc.
Via Business Wire
Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Bolsters Leadership with Chief Operating Officer and Other Key Hires, Reveals Oncology Pipeline
From Nutcracker Therapeutics, Inc.
Via Business Wire
Nutcracker Therapeutics Raises $167 Million in Series C Financing to Advance its mRNA Therapeutics and First-of-its-Kind Biochip-based Manufacturing Platform
From Nutcracker Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.